AI assistant
Barinthus Biotherapeutics plc. — Director's Dealing 2021
May 5, 2021
34488_dirs_2021-05-04_80a5de7b-507a-4c11-933e-d2b13374e554.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Vaccitech plc (VACC)
CIK: 0001828185
Period of Report: 2021-04-29
Reporting Person: Enright William (Director, Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-04-29 | Ordinary Shares | A | 455775 | — | Acquired | 1199229 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-04-29 | Share Option (Right to Buy) | $17 | A | 176130 | Acquired | 2031-04-29 | Ordinary Shares (176130) | Direct |
Footnotes
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2: The Reporting Person was previously granted certain performance-based Restricted Share Units ("RSUs"), the vesting of which was subject to the achievement of certain performance criteria. As of the transaction date, the performance criteria were met, resulting in the vesting of 455,775 RSUs.
F3: This option shall vest and become exercisable in three equal annual installments, with the first installment vesting on April 29, 2022.